Deriving prostate alpha-beta ratio using carefully matched groups, long follow-up and the phoenix definition of biochemical failure

Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1029-36. doi: 10.1016/j.ijrobp.2009.12.058. Epub 2010 Jun 16.

Abstract

Purpose: Prior studies have derived low values of alpha-beta ratio (a/ß) for prostate cancer of approximately 1-2 Gy. These studies used poorly matched groups, differing definitions of biochemical failure, and insufficient follow-up.

Methods and materials: National Comprehensive Cancer Network low- or low-intermediate risk prostate cancer patients, treated with external beam radiotherapy or permanent prostate brachytherapy, were matched for prostate-specific antigen, Gleason score, T-stage, percentage of positive cores, androgen deprivation therapy, and era, yielding 118 patient pairs. The Phoenix definition of biochemical failure was used. The best-fitting value for a/ß was found for up to 90-month follow-up using maximum likelihood analysis, and the 95% confidence interval using the profile likelihood method. Linear quadratic formalism was applied with the radiobiological parameters of relative biological effectiveness = 1.0, potential doubling time = 45 days, and repair half-time = 1 hour. Bootstrap analysis was performed to estimate uncertainties in outcomes, and hence in a/ß. Sensitivity analysis was performed by varying the values of the radiobiological parameters to extreme values.

Results: The value of a/ß best fitting the outcomes data was >30 Gy, with lower 95% confidence limit of 5.2 Gy. This was confirmed on bootstrap analysis. Varying parameters to extreme values still yielded best-fit a/ß of >30 Gy, although the lower 95% confidence interval limit was reduced to 0.6 Gy.

Conclusions: Using carefully matched groups, long follow-up, the Phoenix definition of biochemical failure, and well-established statistical methods, the best estimate of a/ß for low and low-tier intermediate-risk prostate cancer is likely to be higher than that of normal tissues, although a low value cannot be excluded.

MeSH terms

  • Aged
  • Androgen Antagonists / therapeutic use
  • Brachytherapy
  • Confidence Intervals
  • Dose-Response Relationship, Radiation*
  • Follow-Up Studies
  • Humans
  • Likelihood Functions
  • Male
  • Middle Aged
  • Organs at Risk
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / radiotherapy*
  • Relative Biological Effectiveness
  • Research Design
  • Time Factors
  • Treatment Outcome
  • Uncertainty

Substances

  • Androgen Antagonists
  • Prostate-Specific Antigen